45 WIGGINS AVENUE, BEDFORD, MA
Announces Completion of Enrollment of 162 Patients into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Election of Directors at Stoke Therapeutics' 2026 Annual Meeting
Announces First Quarter 2026 Financial Results and Provides Business Updates
Annual Report to Security Holders
Appoints Clare Kahn, Ph.D., to its Board of Directors
Stoke Therapeutics Dismisses KPMG as Independent Auditor
CEO Bonus Approval - Ian F. Smith Granted $697,125 Discretionary Bonus
Material disclosure
Q1
FY 2025
Q3
Q2
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Direct Registration System
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload